RxDoctor Payments Data

Steven Peres

Nurse Practitioner · Jacksonville, FLNPI 1689276073

Payments from drug & device makers

$1,809in general payments, 2019–2025

Across 80 payments — averaging $22.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$961
  • Insulet Corporation$420
  • Novo Nordisk$225
  • Medtronic$58
  • Xeris Pharmaceuticals, Inc.$57
  • Tandem Diabetes Care, Inc.$44
  • plus $43 from 2 others

What the payments were for

  • Food & beverage$1,809100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,809 in reported general payments places this provider in the 80th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$67,273
Medicare patients
479
Services billed
1,199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide164$258,421
JardianceEmpagliflozin114$158,647
MounjaroTirzepatide69$104,804
SomavertPegvisomant13$103,422
TrulicityDulaglutide38$69,158
FarxigaDapagliflozin Propanediol49$47,829
Tresiba Flextouch U-100Insulin Degludec67$44,388
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt38$42,177
Fiasp FlextouchInsulin Aspart (Niacinamide)33$33,663
JanuviaSitagliptin Phosphate21$28,627
Tresiba Flextouch U-200Insulin Degludec19$22,310
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$17,051
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/718$15,929
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$15,093
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog33$13,146

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$225$266,761187 claims
Lilly USA, LLCMounjaro, Trulicity$26$173,962107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →